Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NYSE:FRX NASDAQ:SLS NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.95-1.5%$1.99$1.60▼$2.46$763.65M1.011.28 million shs2.31 million shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsSLSSELLAS Life Sciences Group$1.66+4.4%$1.80$0.77▼$2.27$158.65M2.262.69 million shs1.83 million shsTLRYTilray Brands$0.57-2.1%$0.51$0.35▼$1.98$584.67M1.8547.21 million shs20.44 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group-1.52%-4.88%-2.50%+5.98%-20.41%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%SLSSELLAS Life Sciences Group+4.40%-7.78%-21.70%-4.60%+43.10%TLRYTilray Brands-2.10%-17.40%+17.21%+24.96%-71.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group2.3244 of 5 stars0.05.00.00.02.30.02.5FRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group2.332 of 5 stars3.51.00.00.03.21.70.6TLRYTilray Brands2.8903 of 5 stars3.13.00.00.03.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AFRXForest Road Acquisition 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 3.00Buy$7.00321.69% UpsideTLRYTilray Brands 2.20Hold$1.92237.03% UpsideCurrent Analyst Ratings BreakdownLatest FRX, SLS, CRON, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.39$0.00 per share4,255.14$2.90 per share0.67FRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/ASLSSELLAS Life Sciences Group$1M165.63N/AN/A$0.13 per share12.77TLRYTilray Brands$821.31M0.70$0.15 per share3.81$1.48 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1315.0065.00N/A39.69%-0.07%-0.07%8/7/2025 (Estimated)FRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)TLRYTilray Brands-$244.98M-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest FRX, SLS, CRON, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767N/AN/AN/AN/AN/A8/7/2025Q2 2025CRONCronos Group-$0.02N/AN/AN/A$45.73 millionN/A7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75FRXForest Road AcquisitionN/A0.370.37SLSSELLAS Life Sciences GroupN/A4.644.64TLRYTilray Brands0.202.461.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%FRXForest Road AcquisitionN/ASLSSELLAS Life Sciences Group17.38%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%FRXForest Road AcquisitionN/ASLSSELLAS Life Sciences Group1.40%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million357.53 millionOptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableFRX, SLS, CRON, and TLRY HeadlinesRecent News About These CompaniesTilray Brands, Inc. (TLRY) Expands Beverage Portfolio with Molson Coors AcquisitionAugust 2 at 9:54 AM | insidermonkey.comTilray Brands, Inc. (TLRY) Expands Beverage Portfolio with Molson Coors AcquisitionAugust 2 at 9:54 AM | finance.yahoo.comAtb Cap Markets Estimates Tilray Brands Q1 EarningsAugust 2 at 3:41 AM | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Stock Price Down 2.6% - Here's WhyAugust 1 at 2:00 PM | marketbeat.comShould You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?August 1 at 9:15 AM | zacks.comAtb Cap Markets Weighs in on Tilray Brands Q1 EarningsAugust 1 at 6:57 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Down 1% - Time to Sell?July 31 at 4:24 PM | marketbeat.comTilray Brands, Inc. Stock (TLRY) Opinions on Q4 Earnings ReportJuly 31 at 1:12 PM | quiverquant.comQTilray's Unique Strategy Could Make It A Winner As Cannabis, Beverages, And Wellness MatureJuly 31 at 11:33 AM | benzinga.comInsider Buying: Tilray Brands, Inc. (NASDAQ:TLRY) CFO Buys 33,500 Shares of StockJuly 31 at 7:01 AM | insidertrades.comAtb Cap Markets Forecasts Tilray Brands Q4 EarningsJuly 31 at 7:00 AM | marketbeat.comFY2026 EPS Estimates for Tilray Brands Increased by AnalystJuly 31 at 7:00 AM | marketbeat.comIs Tilray Brands a Dirt Cheap Growth Stock or Just a Bad Buy?July 31 at 6:53 AM | msn.comTilray Brands' (TLRY) "Neutral" Rating Reiterated at Zelman & AssociatesJuly 31 at 2:03 AM | americanbankingnews.comIrwin D. Simon Buys 165,000 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) StockJuly 30 at 7:37 PM | marketbeat.comCarl A. Merton Acquires 33,500 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) StockJuly 30 at 3:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Up 5.4% - Here's WhyJuly 30 at 3:26 PM | marketbeat.comCannabis Stocks Are at a Turning Point: Is Now the Time to Invest?July 30 at 10:35 AM | marijuanastocks.comMTilray Brands Reports In-Line Q4-2025 And FY2025 Results Amidst Weakening SectorJuly 29, 2025 | seekingalpha.comTilray Brands (NASDAQ:TLRY) Shares Down 11.8% - Should You Sell?July 29, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's What HappenedJuly 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the Horizon3 Tech Stocks Poised for Explosive EPS Growth in 2025By Gabriel Osorio-Mazilli | July 8, 2025View 3 Tech Stocks Poised for Explosive EPS Growth in 2025Micron Insiders Sell But Investors Should Buy, Buy, BuyBy Thomas Hughes | July 7, 2025View Micron Insiders Sell But Investors Should Buy, Buy, BuyTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?FRX, SLS, CRON, and TLRY Company DescriptionsCronos Group NASDAQ:CRON$1.95 -0.03 (-1.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.77%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.SELLAS Life Sciences Group NASDAQ:SLS$1.66 +0.07 (+4.40%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.65 -0.01 (-0.60%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tilray Brands NASDAQ:TLRY$0.57 -0.01 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 +0.00 (+0.23%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
